ConductScience.org, home
TM6SF2: transmembrane 6 superfamily member 2
API referenceFor AI assistants

Gene · 53345

Papers1,658

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

41 to 60 of 1,658

Download this page as JSON
TitleJournalYearPMIDFound bySource
Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province.Sci Rep202641866431PubTator, text miningPubMed
Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization.Liver Int202641853930PubTator, text miningPubMed
Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders.Cardiovasc Diabetol Endocrinol Rep202641845551PubTator, text miningPubMed
The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression.JHEP Rep202641810430PubTator, text miningPubMed
Competing Cardiometabolic Pathways of Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease.Gastro Hep Adv202641798891PubTator, text miningPubMed
Reply to: "Gene-environment "amplification" of liver stiffness requires more clinically meaningful analytic approaches".JHEP Rep202641795966PubTator, text miningPubMed
Gene-environment "amplification" of liver stiffness requires more clinically meaningful analytic approaches.JHEP Rep202641795964PubTator, text miningPubMed
Prevalence of high-risk for advanced liver fibrosis using non-invasive scores among type 2 diabetes mellitus patients in the United Arab Emirates: a retrospective cross-sectional study.Front Endocrinol (Lausanne)202641782746PubTator, text miningPubMed
Global, regional, and national burden of nonalcoholic fatty liver disease among adults aged ≥ 45 years: A comprehensive analysis of epidemiological trends and projections to 2035.PLoS One202641779728PubTator, text miningPubMed
Exploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review.Front Pediatr202641777565PubTator, text miningPubMed
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis.BMJ Open Gastroenterol202641775458PubTator, text miningPubMed
Long-term systemic effects of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/MAFLD) in children: a systematic review of persistence and progression into adulthood.Ann Hepatol202641765368PubTator, text miningPubMed
Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction-associated steatotic liver disease and its progression to hepatocellular carcinoma.Front Nutr202641756624PubTator, text miningPubMed
A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation.Nutrients202641754196PubTator, text miningPubMed
Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.J Clin Med202641753348PubTator, text miningPubMed
HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity.J Clin Med202641753255PubTator, text miningPubMed
From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease.J Clin Med202641753223PubTator, text miningPubMed
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.Medicina (Kaunas)202641752724PubTator, text miningPubMed
Genetic Predisposition to MASLD: Potential for Therapeutic Management.Int J Mol Sci202641752069PubTator, text miningPubMed
Reconstructing Liver Fibrosis: 3D Human Models, Microbiome Interfaces, and Therapeutic Innovation.Curr Issues Mol Biol202641751427PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Previous pageNext page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/53345/papers?page=3

API referenceFor AI assistants